Use of the New Smartphone Application for Blood Glucose Monitoring (BGM) with Information-Motivation-Behavioral Skills (IMB) Model Has an Impact on Diabetes Control Parameters
Authors: PARDO SCOTT , ZHUPLATOV SERGEY , WALLACE JANE , BAILEY TIMOTHY S. 
Published: June 2018

The accuracy of the CONTOUR®NEXT ONE BGM system (BGMS), which includes a wireless-enabled BG meter that links to the CONTOUR®Diabetes app installed on a mobile device, has been shown in previous studies. The CONTOUR®Diabetes app Version 2 Prototype detects repeated behavioral patterns in testing results and reports them back to the user. The user can choose to receive recommendations to help eliminate conditions related to the diagnosed pattern. The goal of the interactive app interface implementation is to achieve behavioral change in people with diabetes for better adherence to treatment and sustained glycemic control. The app employs messaging via the IMB model. A 6-week study with 46 insulin-using people with diabetes was performed to assess operational parameters and user reactions to the system. Further to per-protocol analyses, some post-hoc analyses were performed. In addition to a significant decrease in fructosamine level from the beginning to the end of the study (per-protocol analysis), there was a significant decrease in the number of above-target (“high”) blood glucose measurements per week per subject (P &lt;0.0001). This result may be related to a decrease in extreme glycemic fluctuations. The average number of blood glucose tests performed per week increased significantly over the course of the study (P &lt;0.0001), indicating the potential effects of using the system on encouraging patient adherence to treatment and better control of blood glucose levels. While not statistically significant, the average blood glucose values for fasting, before meal, and after meal consistently decreased. A larger study following subjects over a longer time period is required to evaluate the benefits and efficacy of IMB as it relates to glycemic control.

Disclosure

S. Pardo: Employee; Self; Ascensia Diabetes Care. S. Zhuplatov: Employee; Self; Ascensia Diabetes Care. J. Wallace: Employee; Self; Ascensia Diabetes Care. T.S. Bailey: Research Support; Self; Abbott. Consultant; Self; Abbott. Speaker's Bureau; Self; Abbott. Research Support; Self; Ambra BioScience, Ascensia Diabetes Care, Becton, Dickinson and Company. Consultant; Self; Becton, Dickinson and Company. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Calibra Medical. Consultant; Self; Calibra Medical. Research Support; Self; Companion Medical, Dexcom, Inc., Glooko, Inc., GlySens Incorporated, Lexicon Pharmaceuticals, Inc., Eli Lilly and Company. Consultant; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Research Support; Self; Medtronic MiniMed, Inc.. Consultant; Self; Medtronic MiniMed, Inc.. Speaker's Bureau; Self; Medtronic MiniMed, Inc.. Research Support; Self; Novo Nordisk Inc.. Consultant; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Research Support; Self; Sanofi. Consultant; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Research Support; Self; Senseonics. Consultant; Self; Intarcia Therapeutics, Inc.. Research Support; Self; Versartis, Inc., Xeris Pharmaceuticals, Inc., MannKind Corporation.